Ebook: Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics

In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies.

---

In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies.

---

In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies.
Content:
Front Matter....Pages i-vi
B Cell Growth, Differentiation and Malignancies....Pages 1-20
Follicular Lymphoma: Recent Advances....Pages 21-42
Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy....Pages 43-52
Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy....Pages 53-82
EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly....Pages 83-98
HIV and Lymphoma....Pages 99-111
Molecular Biology of Mantle Cell Lymphoma....Pages 113-135
Pathogenesis of Non-Hodgkin Lymphoma Derived from Inflammatory, Autoimmune or Immunologic Disorders....Pages 137-156
Pathogenesis of Non-Hodgkin Lymphoma Derived from Infection Diseases....Pages 157-180
Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy....Pages 181-202
Myelodysplastic Syndromes....Pages 203-240
Chronic Myeloproliferative Disorders:From Molecular Pathogenesis to Targeted Therapy....Pages 241-276
Chronic Myeloid Leukemia....Pages 277-314
Novel Targeted Therapeutics for Acute Myeloid Leukemia....Pages 315-348
Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma....Pages 349-372
Large Granular Lymphocyte Leukemia – From Molecular Pathogenesis to Targeted Therapy....Pages 373-393
Epigenetic Regulation and Therapy in Lymphoid Malignancies....Pages 395-418
Back Matter....Pages 419-426

---

In the last decade, there has been a remarkable explosion of knowledge in hematologic cancer from basic molecular biology and pathology to clinical therapy. This has led to many new advance and insights in the understanding of pathobiology of malignant hematology. New knowledge of disease molecular pathology, cytogenetic, epigenetic and genomic alterations have provided new strategies to attack and eradicate tumor cells at molecular level and significantly impacted our current therapeutics for hematological malignancies. The recent and ongoing rapid expansion of knowledge in this area has become extensive, dynamic and diffuse over the literature and research publications. This has led to the need to capture and compile the new and current information about hematologic cancer with special emphasis on translation from molecular pathobiology to targeted therapeutics. In this book experts from around the world share their thoughts and knowledge about the pathobiology of hematologic cancer, as well as their view on current treatment approaches and future development in these malignant hematologic diseases. This book is well suited for hematology residents, fellows and hematology-oncology physicians, hematopathologist as well as basic research scientist in the area of hematologic malignancies.
Content:
Front Matter....Pages i-vi
B Cell Growth, Differentiation and Malignancies....Pages 1-20
Follicular Lymphoma: Recent Advances....Pages 21-42
Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy....Pages 43-52
Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy....Pages 53-82
EBV-Positive Diffuse Large B-Cell Lymphoma of the Elderly....Pages 83-98
HIV and Lymphoma....Pages 99-111
Molecular Biology of Mantle Cell Lymphoma....Pages 113-135
Pathogenesis of Non-Hodgkin Lymphoma Derived from Inflammatory, Autoimmune or Immunologic Disorders....Pages 137-156
Pathogenesis of Non-Hodgkin Lymphoma Derived from Infection Diseases....Pages 157-180
Hodgkin Lymphoma: From Molecular Pathogenesis to Targeted Therapy....Pages 181-202
Myelodysplastic Syndromes....Pages 203-240
Chronic Myeloproliferative Disorders:From Molecular Pathogenesis to Targeted Therapy....Pages 241-276
Chronic Myeloid Leukemia....Pages 277-314
Novel Targeted Therapeutics for Acute Myeloid Leukemia....Pages 315-348
Novel Targeted Therapeutics for Peripheral T-Cell Lymphoma....Pages 349-372
Large Granular Lymphocyte Leukemia – From Molecular Pathogenesis to Targeted Therapy....Pages 373-393
Epigenetic Regulation and Therapy in Lymphoid Malignancies....Pages 395-418
Back Matter....Pages 419-426
....